U.s. fda approves subcutaneous administration of takeda's entyvio® (vedolizumab) for maintenance therapy in moderately to severely active ulcerative colitis

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the u.s. food and drug administration (fda) has approved a subcutaneous (sc) administration of entyvio® (vedolizumab) for maintenance therapy in adults with moderately to severely active ulcerative colitis (uc) after induction therapy with entyvio intravenous (iv).1 entyvio sc is expected to be available in the u.s. as a single-dose pre-filled pen (entyvio pen) by the end of october. additionally,.
TAK Ratings Summary
TAK Quant Ranking